{"id":390950,"date":"2017-07-07T00:00:00","date_gmt":"2017-07-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0020-2017-biopharma-diabetic-macular-edema-treatment-algorithms-claims-data-analysis-us-2017\/"},"modified":"2026-04-17T05:30:12","modified_gmt":"2026-04-17T05:30:12","slug":"algoop0020-2017-biopharma-diabetic-macular-edema-treatment-algorithms-claims-data-analysis-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0020-2017-biopharma-diabetic-macular-edema-treatment-algorithms-claims-data-analysis-us-2017\/","title":{"rendered":"Diabetic Macular Edema | Treatment Algorithms | Claims Data Analysis | US | 2017"},"content":{"rendered":"<p>Diabetic retinopathy (<abbr data-original-title=\"diabetic retinopathy\" title=\"\">DR<\/abbr>) is an ophthalmic complication of diabetes. In the advanced stages of\u00a0<abbr data-original-title=\"diabetic retinopathy\" title=\"\">DR<\/abbr>, leaking fluid from abnormal blood vessels can cause the macula to swell, impacting sharp vision in the center of the visual field, a\u00a0condition known as diabetic macular edema (<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>). Several current therapies targeting vascular endothelial growth factor (<abbr data-original-title=\"vascular endothelial growth factor\" title=\"\">VEGF<\/abbr>) have been shown to improve visual acuity in\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>\u00a0patients. The most frequently used anti-<abbr data-original-title=\"vascular endothelial growth factor\" title=\"\">VEGF<\/abbr>\u00a0agents in\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>, administered via intravitreal (eye) injections, are Lucentis and Eylea\u2014both approved for the treatment of\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>\u2014and off-label compounded Avastin. In addition to the anti-<abbr data-original-title=\"vascular endothelial growth factor\" title=\"\">VEGF<\/abbr>\u00a0therapies, two long-acting corticosteroid implants,\u00a0Ozurdex and Iluvien, were approved in 2014 for the treatment of\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>. Additionally, some patients may be treated with intravitreal injections of triamcinolone. Given the competitive\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>\u00a0market, it is essential to understand how\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>\u00a0patients are currently being treated using real-world data.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What patient share do key brands garner by line of therapy in\u00a0newly diagnosed\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>patients? What are the quarterly trends in prescribing\u00a0among recently treated and newly diagnosed\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>\u00a0patients?<\/li>\n<li>How have Avastin, Eylea, Iluvien, Lucentis, and Ozurdex been\u00a0integrated into\u00a0the treatment algorithm?<\/li>\n<li>What proportion of\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>\u00a0patients receive drug therapy within a year of\u00a0diagnosis, and how quickly? What percentage of patients progress to later\u00a0lines of therapy within a year of diagnosis?<\/li>\n<li>What percentage of\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>\u00a0patients are treated with monotherapy versus\u00a0combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated\u00a0patients with\u00a0<abbr data-original-title=\"diabetic macular edema\" title=\"\">DME<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390950","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-macular-edema","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390950\/revisions"}],"predecessor-version":[{"id":394074,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390950\/revisions\/394074"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}